|
 |
 |
 |
 |
 |
 |
 |
 |
 |
Select publications
Bhatia RS et al. Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med 2006;355(3):260-9. Abstract
Ewer MS et al. Reversibility of trastuzumab-related cardiotoxicity: New insights based on clinical course and response to medical treatment. J Clin Oncol 2005;23(31):7820-6. Abstract
Giordano SH et al. Congestive heart failure (CHF) in older women treated with anthracycline (A) chemotherapy (C). Proc ASCO 2006;Abstract 521.
Guarneri V et al. Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: The MD Anderson Cancer Center experience. J Clin Oncol 2006;24(25):4107-15. Abstract
McArthur HL et al. A population-based study of adjuvant trastuzumab-mediated cardiotoxicity among early stage HER-2+ breast cancer patients. San Antonio Breast Cancer Symposium 2006;Abstract 2098.
Owan TE et al. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 2006;355(3):251-9. Abstract
Romond EH et al. Trastuzumab plus adjuvant chemotherapy for operable HER 2-positive breast cancer. N Engl J Med 2005;353(16):1673-84. Abstract
Routledge HC et al. Monitoring the introduction of new drugs — Herceptin to cardiotoxicity. Clin Med 2006;6(5):478-81. Abstract
Shepherd LE et al. Left ventricular function following adjuvant chemotherapy for breast cancer: The NCIC CTG MA5 experience. Proc ASCO 2006;Abstract 522.
Sledge GW et al. Adjuvant trastuzumab: Long-term results of E2198. San Antonio Breast Cancer Symposium 2006;Abstract 2075.
Smith KL et al. Cardiac dysfunction associated with trastuzumab. Expert Opin Drug Saf 2006;5(5):619-29. Abstract
Tan-Chiu E et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol 2005;23(31):7811-9. Abstract
 |
 |
